OCT 09, 2019 12:00 PM PDT

Next Steps in Personalized Medicine- Using Genomics and Imaging For Treatment Selection in Early Stage Prostate Cancer

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Medical Science Liaison (Urology), Genomic Health, Inc.
    Biography
      Anson Tharayanil graduated from University of California, Davis with a degree in Biological Sciences. With over a decade of experience in the biotechnology space, he has helped bring several multigene signature tests for breast, colon, and prostate cancer into clinical use. His passion is in educating both physicians and patients on the use and value of genomic tests to optimize cancer care.

    Abstract

    This presentation will review the utility of multiparametric MRI (mpMRI) and genomic testing in the management of early stage prostate cancer and show when and if such tests should be used alone or in combination.
    Prostate cancer (PCa) is the second most frequently diagnosed male malignancy worldwide. In the United States, approximately over 174,000 men are diagnosed with PCa and 31,000 men die of the disease per year.  The majority of PCa diagnosed, however, are low-risk indolent lesions which are not expected to increase disease-specific mortality.  Despite evidence demonstrating the lack of prostate cancer specific-survival benefit in this population, many patients receive immediate curative therapy.
     
    Recently, active surveillance (AS), which monitors patients for disease progression, has been included in the National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines and is increasingly utilized as a treatment option for low- and favorable intermediate-risk patients.  Adoption of AS has been slow as current clinicopathological factors such as patient age, PSA, tumor grade (Gleason score) and tumor volume on biopsy do not adequately risk stratify patients.  
    Newer tools for patient risk stratification such as mpMRI and genomic tests have substantially improved risk stratification so that clinicians can better optimize treatment selection between AS and immediate therapy such as radical prostatectomy or radiation.


    Show Resources
    You May Also Like
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 02, 2020 7:00 AM PDT
    C.E. CREDITS
    SEP 02, 2020 7:00 AM PDT
    DATE: September 2, 2020 TIME: 03:00pm PDT, 6:00pm EDT Spatial omics is an expanding collection of methods to examine biological molecules in their geographical context. By retaining the prec...
    Loading Comments...
    Show Resources
    Attendees
    • See more